MedTrace Logo

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

NCT05477186 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2025-02-21

Study results available
· View outcomes & findings →

Summary

Prevention of COVID-19 caused by SARS-CoV-2.

Conditions

Interventions

BIOLOGICAL

CV0501 (3 μg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV0501 (6 μg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV0501 (12 μg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV0501 (25 μg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV0501 (50 μg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV0501 (100 μg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV0501 (200 μg)

Study vaccine was administered as a single intramuscular injection.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-12
Primary Completion
2023-08-18
Completion
2023-08-18
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Philippines

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05477186 on ClinicalTrials.gov